Document Detail

Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations.
MedLine Citation:
PMID:  8462605     Owner:  NLM     Status:  MEDLINE    
Seventy female patients who had been treated with high doses of iodine-131 for differentiated thyroid cancer (DTC) and who had a subsequent pregnancy were evaluated. The total 131I dose ranged from 1.85 to 16.55 GBq (mean +/- SD = 4.39 +/- 25.20 GBq). Age at first therapy ranged from 15 to 36 years (mean +/- SD = 24.3 +/- 5.0 years) and the interval from 131I therapy to pregnancy varied from 2 to 10 years (mean +/- SD = 5.3 +/- 2.8 years). The estimated radiation dose to the gonads ranged from 10 to 63 cGy (mean +/- SD = 24.0 +/- 13.5 cGy). All patients were treated with L-thyroxine at doses capable of suppressing thyroid-stimulating hormone. Seventy-three children were followed-up and seven pregnancies are still in progress. One child was affected by Fallot's trilogy and three had a low birth weight through with subsequent normal growth; the others were healthy with subsequent normal growth. No newborn with clinical or biochemical thyroid dysfunctions was found. Two spontaneous abortions during the second month of pregnancy were recorded. One of two patients in question subsequently had two healthy children. On the basis of these data, previous administration of high 131I doses does not appear to be a valid reason for dissuading young female DTC patients from considering pregnancy. However, patients should be advised to avoid pregnancy after 131I administration for a period sufficient to ensure complete elimination of the radionuclide and to permit confirmation of complete disease remission, i.e. at least 1 year in our opinion.
D Casara; D Rubello; G Saladini; A Piotto; M R Pelizzo; M E Girelli; B Busnardo
Related Documents :
23774085 - Impact of maternal obesity on fetal health.
2654905 - Solving the mystery of menstrual dysfunction.
24704135 - Examining two different schedules of financial incentives for smoking cessation among p...
11396705 - Pregnancy and iodine.
21339935 - Treatment options for polycystic ovary syndrome.
25251385 - Screening for trisomies 21, 18 and 13 cell-free dna analysis of maternal blood at 10-11...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of nuclear medicine     Volume:  20     ISSN:  0340-6997     ISO Abbreviation:  Eur J Nucl Med     Publication Date:  1993 Mar 
Date Detail:
Created Date:  1993-05-04     Completed Date:  1993-05-04     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7606882     Medline TA:  Eur J Nucl Med     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  192-4     Citation Subset:  IM    
Department of Radiotherapy and Nuclear Medicine, General Hospital of Padua, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / radiotherapy
Carcinoma, Papillary / radiotherapy
Iodine Radioisotopes / therapeutic use*
Ovary / radiation effects
Prenatal Exposure Delayed Effects*
Radiotherapy Dosage
Risk Factors
Thyroid Neoplasms / radiotherapy*
Thyroxine / therapeutic use
Time Factors
Reg. No./Substance:
0/Iodine Radioisotopes; 7488-70-2/Thyroxine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Characteristic and differential calcium signals from cell structures of the root cap detected by ene...
Next Document:  Comparison of simultaneous 99mTc-HMPAO and 111In oxine labelled white cell scans in the assessment o...